Lewis Matthieu, Copland Mhairi, Soverini Simona, Sadovnik Irina, Bedel Aurélie, Prost Stéphane, Italiano Antoine, Mahon François-Xavier
Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, ACTION, INSERM U1218, University of Bordeaux, Bordeaux, Gironde, France.
Institute of Cancer Sciences, University of Glasgow, Glasgow, Glasgow City Counsil, UK.
Hematol Oncol. 2017 Dec;35(4):420-423. doi: 10.1002/hon.2329. Epub 2016 Jul 19.
In the past decade, the treatment of chronic myeloid leukemia (CML) has undergone a drastic evolution. The discovery and success of imatinib and second-generation tyrosine kinase inhibitors have substantially increased the outcome for CML patients. The next step in medical and scientific research is to better understand the malignancy so as to eventually find a cure to eliminate all leukemic cells from patients. One of the key issues is about the resistance of the leukemic stem cells to tyrosine kinase inhibitors. Here, we briefly describe our current studies on CML resistance, and leukemic stem cell modeling and characterization.
在过去十年中，慢性髓性白血病（CML）的治疗发生了巨大变革。伊马替尼及第二代酪氨酸激酶抑制剂的发现与成功应用，显著改善了CML患者的治疗效果。医学和科学研究的下一步是更深入地了解这种恶性肿瘤，以便最终找到治愈方法，从患者体内清除所有白血病细胞。其中一个关键问题是白血病干细胞对酪氨酸激酶抑制剂的耐药性。在此，我们简要介绍我们目前关于CML耐药性以及白血病干细胞建模与表征的研究。
